

16 January 2012

## **Myozyme manufactured at 160 litre capacity in the USA**


I would like to reassure all within the International Pompe Community that the IPA is fully aware of the current issues surrounding the supply of Myozyme in the USA; that is to say Enzyme Replacement Therapy (ERT) for Pompe disease manufactured at the 160 litre capacity. We are liaising closely with Genzyme and the AMDA and are happy that the management and communications are working well and in the best interests of the patients and families concerned.

The short supply issue relates only to patients who currently receive the 160 litre supply, all of whom reside in the USA; it does not affect the supply of ERT for Pompe disease produced at the higher capacity of 4000 litres – Lumizyme (USA) and Myozyme (Rest of the world). The supply of 4000 litre material is extremely healthy and we are assured that it will not be affected by the small number of additional patients receiving it during the Advance trial recently initiated by Genzyme.

If you have any questions about the current supply issue please contact either your national patient representative or an IPA representative. Contact information for both is available on the IPA website:

<http://worldpompe.org/affiliates>

<http://worldpompe.org/about-us/ipa-board>

A handwritten signature in black ink, appearing to read 'Allan Muir', with a long horizontal flourish underneath.

Allan Muir  
Chairman, International Pompe Association  
Email [allan@pompe.org.uk](mailto:allan@pompe.org.uk)  
Web [www.worldpompe.org.uk](http://www.worldpompe.org.uk)